Corporate - Media & Press - Press Release
Arrayit Diagnostics Names Elite Financial Communications Group as Investor Relations/Public Relations Counsel
Source: Arrayit Diagnostics, Inc.
On 9:24 am EST, Monday November 30, 2009
HOUSTON, Nov. 30 /PRNewswire/ -- Arrayit Diagnostics, Inc., a majority-owned subsidiary of Arrayit Corporation (OTC Bulletin Board: ARYC - News), today announced the appointment of Elite Financial Communications Group, LLC, a fully integrated marketing and communications firm, as the Company's investor and public relations counsel of record.
Working closely with Arrayit Diagnostics' leadership team, Elite is tasked with developing a comprehensive communications platform that will proactively leverage management's strategic vision and industry expertise, and provide meaningful insight into the Company's operational and financial performance, compelling growth strategy and long term value proposition. In addition, Elite will assist in the development of customized, high impact and fully integrated public and media relations programs designed to increase industry and investor awareness of the Company's novel microarray-based diagnostic products, services and industry thought leadership.
Dodi Handy, President and CEO of Elite, noted, "Given Arrayit Diagnostics' near term strategy to commercialize a series of proprietary diagnostic tests using microarray technology capable of detecting specific disease states in their early stages, the coming year promises to be one defined by potentially remarkable growth opportunities for the Company. As such, Elite looks forward to ensuring that due attention is focused on Arrayit Diagnostics as it progresses its compelling business plan and earns distinction for the important role it intends to play in the fast evolving genomic and proteomics industry."
About Elite Financial Communications Group, LLC
Headquartered in Lake Mary, Florida, Elite Financial Communications Group (EFCG) combines a fully integrated array of award-winning investor and public relations services with diverse expertise, influence, talent and capabilities to achieve quantifiable results for both publicly traded and privately held companies. Elite Media Group, a division of EFCG, specializes in media relations, corporate communications, brand building, professional copywriting, event planning, crises management and government relations. Elite Digital Strategies Group concentrates on leveraging social media and digital communications to expand reach and increase awareness of its clients among investors, media professionals and strategic business connections. For more information, please visit www.efcg.net.
About Arrayit Corporation
Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the genetic, research, pharmaceutical and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. It now offers over 650 products to a customer base of more than 10,000 laboratories worldwide, including almost every major university, pharmaceutical and biotechnology company, major agricultural and chemical companies, government agencies, national research foundations and many private sector enterprises. Please visit www.arrayit.com for more information.
About Arrayit Diagnostics, Inc.
Houston-based Arrayit Diagnostics, Inc., a majority-owned subsidiary of Arrayit Corporation, is actively engaged in developing and commercializing a series of proprietary microarray-based diagnostic tests that provide for early detection of cancers, neurodegenerative diseases and other chronic and severe disease states.
Safe Harbor Statement
Except for historical information contained herein, statements made in this release that constitute forward-looking statements are based on currently available information, involve certain risks and uncertainties and the Company assumes no responsibility to update any such forward-looking statement. The following factors, among others, may cause actual results to differ materially from the results suggested in the forward-looking statements. Risks that may result from changes in the Company's business operations; our ability to keep pace with technological advances; significant competition in the biomedical business; our relationships with key suppliers and customers; quality and consumer acceptance of newly introduced products; market volatility; non-availability of product; excess inventory; price and product competition; new product introductions, the outcome of our legal disputes; the possibility that the review of our prior filings by the SEC may result in changes to our financial statements; and the possibility that stockholders or regulatory authorities may initiate proceedings against Arrayit and/or our officers and directors as a result of any restatements. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form 10-K/A for the fiscal year ended December 31, 2008 and Form 10-Q/A for the fiscal first quarter ended March 31, 2009, Form 10-Q/A for the fiscal second quarter ended June 30, 2009 and Form 10-Q/A for the fiscal third quarter ended September 30, 2009.
Copyright 1993-2018 Arrayit Corporation. All rights reserved.